Correlation of epidermal growth factor receptor score with prognostic variables in transitional cell carcinoma of urinary bladder among north-eastern Indian population
DOI:
https://doi.org/10.18203/2349-2902.isj20183727Keywords:
Epidermal growth factor receptor score, Prognostic variables, Transitional cell carcinoma bladderAbstract
Background: Epidermal growth factor receptor (EGFR) has demonstrated over expression in bladder tumours and correlation with stage and grade of tumours. The aim of present study was to find the relation between score of the EGFR in Transitional Cell Carcinoma (TCC) of bladder and its various prognostic variables.
Methods: This is a retrospective study conducted in Dept of Urology, Gauhati Medical College Hospital between Dec 2016 and July 2017. Forty cases of TCC bladder that were operated either by TURBT or radical cystectomy have been taken. However, patients with CKD, pre-existing systemic disease and UTI were excluded from the study. Presence of EGFR and its score were analysed. The rating was done as 0 (non-immunoreactive), 1+ (weak), 2+ (moderate) and 3+ (strong). The correlation between EGFR score and the various factors like age, sex, stage, size of tumour, presence of CIS, tumour grade, muscle invasion, number of tumours and type of stalk were evaluated statistically using chi square tests.
Results: Average age is 59.825 years and male to female ratio is 5.6:1. EGFR score is not significantly related with age, sex, stage of disease, muscle invasiveness or number of tumours whereas size of tumour, presence of CIS changes, grade of TCC and type of tumour stalk bears statistically significant relation with EGFR score.
Conclusions: Studies have shown EGFR positivity to be associated with high tumour stage, tumour progression, and poor clinical outcome. Authors have found size >3cm, CIS changes, high grade tumours and broad-based stalks to be significantly associated with higher EGFR scores among patients with TCC of bladder.
Metrics
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86.
Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun 1;27(3):289-93.
Nand KA. Consolidated report of population-based cancer registeries. Indian Counc Med Res. 2001;1:212.
Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clinics North Am. 1992 Aug;19(3):435-53.
Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986 May 1;135(5):920-2.
Greene LF, Hanash KA, Farrow GM. Benign papilloma or papillary carcinoma of the bladder?. J Urol. 1973 Aug 1;110(2):205-7.
Tut VM, Hildreth AJ, Kumar M, Mellon JK. Does voided urine cytology have biological significance?. British J Urol. 1998 Nov 1;82(5):655-9.
Lutzeyer W, Rübben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982 Feb 1;127(2):250-2.
Heney NM, Nocks BN, Daly JJ, Prout GR, Newall JB, Griffin PP, et al. Ta and T1 bladder cancer: location, recurrence and progression. BJU Int. 1982 Apr 1;54(2):152-7.
Kurth KH, Denis L, Bouffioux CH, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumours. Europ J Cancer. 1995 Oct 1;31(11):1840-6.
Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?. J Urol. 1987 Jan 1;137(1):39-43.
De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli Groux B, Van Der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFß-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int J Cancer. 1997;71:284-91.
De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. J Cellular Physiol. 2008 Mar 1;214(3):559-67.
Łukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117(5-6):247-51.
Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990 Apr 1;65(7):1619-25.
Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. British J Cancer. 1994 Jun;69(6):1120.
Mellon K, Wright C, Kelly P, Horne CW, Neal DE. Bladder cancer: long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995 Mar 1;153(3):919-25.
Chow NH, Liu HS, Lee EI, Chang CJ, Chan SH, Cheng HL, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997;17(2B):1293-6.
Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Reviews. 1992 Feb 1;13(1):3-17.
Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clinical Cancer Res. 1999 Mar 1;5(3):577-86.
Epstein JI, Amin MB, Reuter VR, Mostofi FK, Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998 Dec 1;22(12):1435-48.
Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiation Oncol Biol Physics. 2004 Jun 1;59(2):S21-6.
Nakanishi K, Kawai T, Suzuki M, Torikata C. Growth factors and oncogene products in transitional cell carcinoma. Mode Pathol: An Official J United States Canadian Academy Pathol, Inc. 1996 Mar;9(3):292-7.
Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clinical Cancer Res. 2001 Jul 1;7(7):1957-62.
Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res. 1997 Jan 1;25(1):9-17.
Parvin M, Sabet-Rasekh P, Hajian P, Torbati PM, Sabet-Rasekh P, Mirzaei H. Evaluating the prevalence of the epidermal growth factor receptor in transitional cell carcinoma of bladder and its relationship with other prognostic factors. Iranian J Cancer Prevention. 2016 Feb;9(1).
Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007 May 15;109(10):2016-24.
Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer?. BJU Int. 1999 Mar 1;83:498-503.
Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: a multivariate survival analysis. Am J Clinical Pathol. 1994 Feb 1;101(2):166-76.
Liukkonen TJ, Lipponen PK, Helle M, Jauhiainen KE. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Urol Res. 1997 Jan 1;25(1):1-8.
Bue P, Wester K, Sjostrom A, Holmberg A, Nilsson S, Carlsson J, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. J Urol. 1998 Nov 1;160(5):1937-8.
Nicholson RI, Gee JM, Harper M2. EGFR and cancer prognosis. Europ J Cancer. 2001 Sep 1;37:9-15.
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005 Nov 15;65(22):10524-35.
Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol. 2006 Aug 1;176(2):787-92.
Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015 Jan 1;193(1):19-29.
